India, June 18 -- Alvotech (ALVO), a commercial-stage biotechnology company, on Thursday announced the closing of its previously declared, unwritten public offering of $26.07 million ordinary shares at an offering price of $3.75 per share on June 17, 2026.
In connection with the offering, the company has entered into subscription agreements with certain investors for a concurrent offering of $17.83 million ordinary shares at a price of $3.75 per share.
The gross proceeds from the concurrent offering are estimated to be approximately $67 million. The company expects to close the concurrent placement on or about June 25, 2026, subject to customary conditions.
The Alvotech Board has approved issuing $43.89 million shares to investors partic...